Latest News Filter by: All2023202220212020June 1, 2023 Ventus Therapeutics to Present at the Canadian Chemistry Conference and Exhibition May 1, 2023 Ventus Therapeutics Hosts Inaugural Program Spotlight: VENT-03, a First-in-Class cGAS Inhibitor April 20, 2023 Ventus Therapeutics Awarded Grant by The Michael J. Fox Foundation to Support Development of a NLRP3 PET Tracer April 17, 2023 Ventus Therapeutics Provides Updates on cGAS Inhibitor Program at Keystone Symposium on Innate Immunity April 13, 2023 Ventus Therapeutics to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference January 5, 2023 Ventus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference January 4, 2023 Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise December 1, 2022 Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit October 6, 2022 Ventus Therapeutics Chief Scientific Officer Michael Crackower, Ph.D., to Present on ReSOLVE™ Platform at Next Generation Undruggable Conference September 29, 2022 Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program September 6, 2022 Ventus Therapeutics Opens New Facility in Waltham, MA as First Phase of Global Expansion July 7, 2022 Ventus Therapeutics Promotes Daniel Koerwer to Chief Operating Officer May 9, 2022 Ventus Therapeutics Awarded Grant by the U.S. Department of Defense to Study the Role of cGAS in Lupus May 2, 2022 Ventus Therapeutics Appoints Stuart Green, M.D., as Chief Medical Officer April 4, 2022 Ventus Therapeutics Appoints Victor Lobanov, PhD, as Head of Computational Sciences March 31, 2022 Ventus Therapeutics Appoints Christine Ha as Chief Financial Officer February 9, 2022 Ventus Therapeutics Closes $140 Million Series C Financing January 6, 2022 Ventus Therapeutics Announces Publication in Journal of Experimental Medicine Describing Advances in Structure-based Drug Discovery for Inflammasome Targets December 17, 2021 Ventus Therapeutics Appoints John Chodera, Ph.D. and Tom Kurtzman, Ph.D. to its Scientific Advisory Board December 7, 2021 Ventus Therapeutics Appoints Three New Members to Board of Directors November 18, 2021 Ventus Therapeutics to Present Data for Novel Brain-Penetrant NLRP3 Small Molecule Inhibitors for the Treatment of Inflammatory and Neurological Diseases November 3, 2021 Ventus Therapeutics to Present Data on Novel cGAS Small Molecule Inhibitors in the Modulation of Auto-Inflammation September 24, 2021 Ventus Therapeutics to Present Data for Novel Peripherally Restricted and Brain-Penetrant NLRP3 Small Molecule Inhibitors for the Treatment of Inflammatory and Neurological Diseases September 7, 2021 Ventus Therapeutics Appoints Christopher Bayly, PhD to its Scientific Advisory Board July 20, 2021 Ventus Therapeutics Strengthens Computational Team and Capabilities April 8, 2021 Ventus Therapeutics Closes $100 Million Series B Financing January 25, 2021 Ventus Announces Promotion of Michael Crackower, PhD, to Chief Scientific Officer November 16, 2020 Ventus Therapeutics Named to C&E News 10 Start-Ups to Watch 2020 List September 15, 2020 Ventus Therapeutics Appoints Industry Veteran, Steven James, to Board of Directors May 6, 2020 Ventus Therapeutics Launches with $60 Million Series A